Urogen Pharma (NASDAQ:URGN) Insider Mark Schoenberg Sells 10,000 Shares

Key Points

• Urogen Pharma insider Mark Schoenberg sold 10,000 shares at an average price of $17.69, reducing his stake by 6.32% to 148,229 shares, valued at approximately $2.62 million.
• The company's recent quarterly earnings report showed a loss of ($1.05) EPS, missing analysts' expectations, but revenue of $24.22 million surpassed estimates.
• Analysts remain optimistic about Urogen Pharma, maintaining a consensus "Buy" rating with an average target price of $31.43, despite fluctuations in target prices from various firms.

Urogen Pharma (NASDAQ:URGN - Get Free Report) insider Mark Schoenberg sold 10,000 shares of the business's stock in a transaction on Monday, August 11th. The stock was sold at an average price of $17.69, for a total value of $176,900.00. Following the completion of the transaction, the insider directly owned 148,229 shares in the company, valued at approximately $2,622,171.01. This represents a 6.32% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Mark Schoenberg also recently made the following trade(s):

• On Monday, July 28th, Mark Schoenberg sold 5,149 shares of Urogen Pharma stock. The stock was sold at an average price of $19.14, for a total value of $98,551.86.
• On Monday, June 9th, Mark Schoenberg sold 5,162 shares of Urogen Pharma stock. The stock was sold at an average price of $7.37, for a total value of $38,043.94.

Urogen Pharma Stock Performance

NASDAQ:URGN traded up $0.57 on Wednesday, reaching $19.77. The company's stock had a trading volume of 325,964 shares, compared to its average volume of 1,574,805. Urogen Pharma has a 1-year low of $3.42 and a 1-year high of $21.01. The firm has a market cap of $914.45 million, a PE ratio of -5.95 and a beta of 1.12. The business's 50-day moving average price is $14.61 and its two-hundred day moving average price is $11.46.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.23). Urogen Pharma had a negative net margin of 164.44% and a negative return on equity of 97,487.15%. The business had revenue of $24.22 million during the quarter, compared to analyst estimates of $23.06 million. As a group, sell-side analysts expect that Urogen Pharma will post -3.12 EPS for the current year.

Wall Street Analysts Forecast Growth

URGN has been the subject of a number of recent research reports. HC Wainwright dropped their target price on Urogen Pharma from $50.00 to $40.00 and set a "buy" rating for the company in a research report on Monday. Oppenheimer set a $31.00 target price on Urogen Pharma and gave the stock a "buy" rating in a research report on Friday, June 13th. The Goldman Sachs Group set a $16.00 target price on Urogen Pharma and gave the stock a "neutral" rating in a research report on Friday, June 13th. Scotiabank restated an "outperform" rating on shares of Urogen Pharma in a research report on Friday, June 13th. Finally, D. Boral Capital restated a "buy" rating and set a $25.00 target price on shares of Urogen Pharma in a research report on Tuesday, August 5th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Urogen Pharma has an average rating of "Buy" and a consensus target price of $31.43.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. RA Capital Management L.P. acquired a new position in shares of Urogen Pharma during the first quarter worth about $35,461,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Urogen Pharma by 216.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,360,524 shares of the company's stock worth $48,227,000 after buying an additional 2,983,368 shares during the period. Toronto Dominion Bank acquired a new position in shares of Urogen Pharma during the fourth quarter worth about $18,628,000. Acorn Capital Advisors LLC acquired a new position in shares of Urogen Pharma during the fourth quarter worth about $16,149,000. Finally, Nantahala Capital Management LLC acquired a new position in shares of Urogen Pharma during the fourth quarter worth about $14,608,000. 91.29% of the stock is owned by institutional investors and hedge funds.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.